Richard Siegel

Dr. Richard Siegel


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2007 in Immunity
Verified
Journal Article
Closed access
ALArian Laurence
Arian Laurence
CTCristina M. Tato
Cristina M. Tato
TDTodd S. Davidson
Todd S. Davidson
YKYuka Kanno
Yuka Kanno
ZCZhi Jane Chen
Zhi Jane Chen
JOJohn J. O'SHea
John J. O'SHea

31 January 2011 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ABAriel C. Bulua
Ariel C. Bulua
ASAnna Simon
Anna Simon
RMRavikanth Maddipati
Ravikanth Maddipati
MPMartin Pelletier
Martin Pelletier
HPHeiyoung Park
Heiyoung Park
RSRichard Siegel
Richard Siegel
Reactive oxygen species (ROS) have an established role in inflammation and host defense, as they kill intracellular bacteria and have been shown to activate the NLRP3 inflammasome. Here, we find that ROS generated by mitochondrial respiration are important for normal lipopolysaccharide (LPS)-driven production of several proinflammatory cytokines and for the enhanced responsiveness to LPS seen in cells from patients with tumor necrosis factor receptor-associated periodic syndrome (TRAPS), an autoinflammatory disorder caused by missense mutations in the type 1 TNF receptor (TNFR1). We find elevated baseline ROS in both mouse embryonic fibroblasts and human immune cells harboring TRAPS-associated TNFR1 mutations. A variety of antioxidants dampen LPS-induced MAPK phosphorylation and inflammatory cytokine production. However, gp91phox and p22phox reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunits are dispensable for inflammatory cytokine production, indicating that NADPH oxidases are not the source of proinflammatory ROS. TNFR1 mutant cells exhibit altered mitochondrial function with enhanced oxidative capacity and mitochondrial ROS generation, and pharmacological blockade of mitochondrial ROS efficiently reduces inflammatory cytokine production after LPS stimulation in cells from TRAPS patients and healthy controls. These findings suggest that mitochondrial ROS may be a novel therapeutic target for TRAPS and other inflammatory diseases.

1 May 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
SWShu Wang
Shu Wang
JWJingya Wang
Jingya Wang
VKVarsha Kumar
Varsha Kumar
JKJodi L Karnell
Jodi L Karnell
BNBrian Naiman
Brian Naiman
RERachel Ettinger
Rachel Ettinger
Although the aetiology of systemic lupus erythematosus (SLE) is unclear, dysregulated B cell responses have been implicated. Here we show that an unusual CD11chiT-bet+ B cell subset, with a unique expression profile including chemokine receptors consistent with migration to target tissues, is expanded in SLE patients, present in nephrotic kidney, enriched for autoreactive specificities and correlates with defined clinical manifestations. IL-21 can potently induce CD11chiT-bet+ B cells and promote the differentiation of these cells into Ig-secreting autoreactive plasma cells. While murine studies have identified a role for T-bet-expressing B cells in autoimmunity, this study describes and exemplifies the importance of CD11chiT-bet+ B cells in human SLE.

1 October 2004 in Immunity
Verified
Journal Article
Closed access
JMJagan R. Muppidi
Jagan R. Muppidi
JTJürg Tschopp
Jürg Tschopp
RSRichard Siegel
Richard Siegel

9 March 2017 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
PDF file
MCMichael Croft
Michael Croft
RSRichard Siegel
Richard Siegel

1 April 2006 in Nature Reviews Immunology
Verified
Journal Article
Closed access
RSRichard Siegel
Richard Siegel